News

89bio to Showcase Pegozafermin Trial Insights at Major Conference

89bio to Showcase Pegozafermin Trial Insights at Major Conference

89bio Presents Key Findings from ENLIVEN Phase 2b Trial

89bio, Inc. (NASDAQ: ETNB), a biopharmaceutical company committed to developing innovative treatments for liver and cardiometabolic diseases, has exciting news. The company will present new analyses from its Phase 2b ENLIVEN trial, which assesses the efficacy of pegozafermin in patients suffering from metabolic dysfunction-associated steatohepatitis (MASH) with fibrosis, during the esteemed AASLD The Liver Meeting® 2024.

Poster Presentation Highlights

At the upcoming meeting scheduled for November, four poster presentations will spotlight significant findings from the ENLIVEN trial.

Key Abstracts and Presenting Authors

The abstracts include:

  • Biomarker response in MASH patients with high-risk baseline FAST scores: Findings by Naim Alkhouri, MD, will be revealed on November 15 from 8:00 AM to 5:00 PM PST.
  • Pegozafermin's impact on cirrhosis progression: A post-hoc analysis presented by Jörn M. Schattenberg, MD, on November 15 from 8:00 AM to 5:00 PM PST.
  • Machine Learning Insights: An analysis by Oliver Mansbach, BA/BS, scheduled for November 16 from 8:00 AM to 5:00 PM PST.
  • Diagnostic potential of FAST and AGILE3+ scores: Presented again by Naim Alkhouri, MD, on November 16 from 8:00 AM to 5:00 PM PST.

Understanding MASH and Its Treatment

Metabolic dysfunction-associated steatohepatitis (MASH), a serious form of liver disease, is characterized by liver fat accumulation, inflammation, and potential fibrosis. With rising numbers projected to affect millions, it is crucial to target treatments aimed at improving liver health and reducing complications such as cirrhosis and cardiovascular implications.

Treating advanced fibrosis requires a multidisciplinary approach, emphasizing the importance of timely intervention to prevent complications. MASH's complex nature necessitates effective therapeutic strategies to significantly enhance patient outcomes.

Insights into the ENLIVEN Trial

The ENLIVEN trial, a pivotal Phase 2b study, was meticulously designed to evaluate the safety and efficacy of weekly or biweekly pegozafermin dosing. Involving 192 participants, the study's primary goals focused on resolution rates of MASH and improvements in fibrosis staging after 24 weeks.

Results demonstrated remarkable efficacy, achieving high statistical significance—particularly with the 30 mg QW and 44 mg Q2W dosing regimens. These findings significantly contribute to understanding pegozafermin's therapeutic potential, with published results available for further exploration.

The Mechanism of Pegozafermin

Pegozafermin, an engineered glycoPEGylated analog of fibroblast growth factor 21, aims to combat MASH and related hypertriglyceridemia. Clinical trials have highlighted its ability to not only reduce triglyceride levels but also improve insulin sensitivity and liver inflammation, showcasing its broad therapeutic profile.

About 89bio and Future Directions

Headquartered in San Francisco, 89bio is dedicated to creating and advancing best-in-class solutions for individuals struggling with liver and metabolic diseases. With an active focus on moving pegozafermin swiftly through clinical trials, the company exemplifies commitment in an area desperately needing innovation.

The firm is pursuing exciting developments not only in MASH but also in related indications through ongoing Phase 3 trials, positioning itself favorably within the biopharmaceutical landscape.

Frequently Asked Questions

What is the ENLIVEN trial?

The ENLIVEN trial is a Phase 2b study evaluating the safety and effectiveness of pegozafermin in treating patients with metabolic dysfunction-associated steatohepatitis (MASH).

What are the key findings from the recent posters at AASLD?

The posters showcase various analyses, including biomarker responses, potential impacts on fibrosis progression, and the use of machine learning in treatment assessments.

What is the significance of pegozafermin?

Pegozafermin is designed to address the complex issues of MASH and severe hypertriglyceridemia, demonstrating promising results in improving liver function and metabolic parameters.

How does MASH affect patients?

MASH can lead to serious liver complications, including cirrhosis and hepatocellular carcinoma, greatly affecting patients' overall health and survival.

Where can I find more information about 89bio?

For detailed insights, you may contact 89bio directly or visit their official website.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Hanmi Compressor Tests Vietnam Before Wider Expansion

Updated Category News Views 29

Compressed air is the sort of factory necessity nobody brags about until it fails, and that is precisely why Hanmi Compressor’s Vietnam plan deserves a sober look. The Daegu-based specialist is not arriving with a grand export victory lap. It is still building the front door: a website, a promotional video, and a process for finding Vietnamese manufacturers and...

Continue Reading
Alpha's Training Bet Reaches Into Aesthetic Care Networks

Updated Category News Views 213

Training is becoming part of the operating machine A certificate course is rarely the headline-grabber in healthcare services, yet this one deserves a closer look. Alpha Aesthetics Partners has launched Practice Aesthetics, a unified clinical education platform tied directly to its expanding network of medical aesthetics practices. This is not a public-market ticker...

Continue Reading
STORMER LAT Targets Sewer Crews' Costly Access Delays

Updated Category News Views 65

A buried cleanout can turn a simple sewer inspection into a scheduling circus. That unglamorous headache is exactly where FIBERSCOPE is aiming its new STORMER LAT Lateral Launch Camera System, announced November 17, 2026. This is not some flashy consumer gadget hunting for attention; it is field equipment built around a painfully ordinary municipal problem: crews often...

Continue Reading
MacDill Mold Case Puts Privatized Housing on Notice

Updated Category News Views 99

Four hundred fifty-four people are a hard number to shrug off. The expanded civil case over alleged toxic mold conditions at MacDill Air Force Base now covers 105 military families, up from 39 households when it was filed in September 2025. Their complaint against The Michaels Organization and affiliated entities may be the largest known military-housing lawsuit in the...

Continue Reading
Historic China-Russia-US Summit Aims for Global Stability

Updated Category News Views 85

The Weight of History in Shenzhen When the big players decide to talk face-to-face, it's more than just a photo op. This week in Shenzhen, the leaders of China, Russia, and the United States are doing just that. And let me tell you, it's the kind of gathering that can either stabilize the gears of global politics or grease the wheels of tension. This chinwag isn't just...

Continue Reading
Inhibrx Ewing Data Gives Ozekibart a Real Clinical Signal

Updated Category News Views 141

Numbers this lopsided in relapsed Ewing sarcoma make me sit up straight, even after years of watching oncology releases try to turn every blip into a brass band. Inhibrx has reported updated Phase 1/2 data for ozekibart, paired with irinotecan and temozolomide, that look genuinely notable in a disease where patients have very few good cards left to play. That matters...

Continue Reading
BioArctic's Q3 Call Puts Leqembi Economics Under Watch

Updated Category News Views 32

One Date, Several Unanswered Questions November 25 lands with an unusually clean checklist for BioArctic watchers: results arrive at 8:00 a.m. CET, then management takes the floor at 9:30 a.m. CET. That is the whole immediate event, and it matters because this is not a company investors can sensibly judge by a single headline or a vague promise about neuroscience....

Continue Reading
LONGi's Solar-Storage Push Faces Africa's Cost Wall

Updated Category News Views 22

A vaccine refrigerator humming through a blackout is more meaningful than another climate-conference slogan. That was the useful thread running through LONGi's November 13 COP31 side event in Antalya, Türkiye: solar and storage are not merely hardware for remote communities. When designed, financed and maintained properly, they can keep clinics, water pumps and other...

Continue Reading
Visa Direct Tests Stablecoin Prefunding in Asia-Pacific

Updated Category News Views 149

Cross-border payouts have always had an ugly little problem: money can move digitally in theory, then sit around waiting for banks to wake up in practice. Triple-A’s new collaboration with Visa Direct aims straight at that nuisance in Asia-Pacific, allowing eligible clients to use stablecoins to prefund cross-border payouts while the recipient still gets local currency....

Continue Reading
Midea's Cooling Systems Take Center Stage at DCW ME

Updated Category News Views 121

AI Surge Demands Cooler Solutions Alright, who'd guess that data centers would feel the heat—literally—like a welder's furnace in Abu Dhabi? As AI demand burns hotter across the Middle East, data centers are sweating it out against 50°C-plus temperatures. We're talking about some serious pressure on traditional cooling methods that just can’t cut it anymore....

Continue Reading

Top 5 Most Recently Viewed Articles

Securities Fraud Investigation Casts Shadow on Driven Brands

Updated Category News Views 331

The Unfolding Drama Surrounding Driven Brands Out of nowhere, the waters are getting choppy for Driven Brands Holdings, and it’s not just a casual dip; more like a tsunami warning. Ademi LLP is cranking up the heat with an investigation into possible securities fraud that’s got investors scratching their heads and probably running for cover. What’s the Big Deal?...

Continue Reading
Info-Tech Research Group Expands Focus in Asia-Pacific Markets

Updated Category News Views 292

Info-Tech Research Group Expands Its Global Footprint Info-Tech Research Group has recently expanded its global presence by launching a new office in Singapore while significantly ramping up investments in New Zealand. This strategic move enables the firm to provide more localized, outcome-driven support to IT leaders throughout Southeast Asia and the Australia-New...

Continue Reading
Laramide Resources' Strategic Exploration Plans in Kazakhstan

Updated Category News Views 144

Exploration Drilling Plans by Laramide Resources Laramide Resources Ltd., a leading organization in uranium exploration, has identified multiple promising targets within its Chu-Sarysu Project. This initiative is set to take place in a mineral-rich area renowned for its potential to yield significant deposits of uranium and other valuable minerals like rare earth elements...

Continue Reading
Stravito Unveils AI Personas for Accelerated Market Insights

Updated Category News Views 311

Stravito Introduces AI Personas for Enhanced Market Positioning Stravito supports brands in rapidly validating their ideas using advanced AI technology. In a dynamic market environment, Stravito has launched an initiative designed to drastically improve the speed and reliability of idea testing for brands. This revolutionary tool, known as Stravito AI Personas, transforms...

Continue Reading
Duni Introduces Innovative Take-Away Series Boosting Sustainability

Updated Category News Views 245

Duni Introduces Innovative Take-Away Series Boosting Sustainability Duni is excited to unveil a fresh series of take-away packaging that represents a significant leap towards sustainability. The company has developed new packaging solutions that feature a grey plastic base, which can significantly enhance recycling efforts compared to traditional black plastic. This move...

Continue Reading